Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30721496 | 1.00 | NPC1 (0.67) | NPC1RAB9ASMN1; SMN2KDM4EMAPT | |
| SCHEMBL7272079 | 0.82 | NPC1 (0.80) | NPC1RAB9ASMN1; SMN2KDM4EMAPT | |
| SCHEMBL695898 | 0.81 | SMN1; SMN2 (0.59) | NPC1RAB9ASMN1; SMN2KDM4EMAPT | |
| SCHEMBL8870631 | 0.81 | LMNA (0.52) | NPC1RAB9ASMN1; SMN2KDM4EMAPT | |
| SCHEMBL10394613 | 0.80 | SMN1; SMN2 (0.57) | NPC1RAB9ASMN1; SMN2KDM4EMAPT | |
| SCHEMBL600676 | 0.79 | PDPK1 (0.61) | MAPTMTNR1AMTNR1BALDH1A1CA12 | |
| SCHEMBL1988494 | 0.79 | PDPK1 (0.61) | MAPTMTNR1AMTNR1BALDH1A1CA12 | |
| SCHEMBL2466144 | 0.79 | PDPK1 (0.61) | MAPTMTNR1AMTNR1BALDH1A1CA12 | |
| SCHEMBL8029932 | 0.79 | PDPK1 (0.61) | MAPTMTNR1AMTNR1BALDH1A1CA12 | |
| SCHEMBL7272139 | 0.77 | LMNA (0.58) | RAB9AKDM4EMAPTLMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114516808-A | Preparation method of amino-protected benzocycloketone compound | 华东师范大学 | 2022-05-20 | — | — | CN | disclosed |
| US-8569294-B2 | 2-(cyclic amino)-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-10-29 | — | — | US | disclosed |
| US-8569294-B2 | 2-(cyclic amino)-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-10-29 | — | — | US | disclosed |
| US-8569294-B2 | 2-(cyclic amino)-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-10-29 | — | — | US | disclosed |
| EP-2423207-A2 | 2-(cyclic amino)-pyrimidone derivatives as TPK1 inhibitors | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-02-29 | — | — | EP | disclosed |
| EP-2423207-A2 | 2-(cyclic amino)-pyrimidone derivatives as TPK1 inhibitors | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-20090233918-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-09-17 | — | — | US | disclosed |
| US-20090233918-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-09-17 | — | — | US | disclosed |
| US-20090233918-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-09-17 | — | — | US | disclosed |
| WO-2007119463-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES AS TPK1 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-10-25 | — | — | WO | disclosed |
| US-5128362-A | Antidepressant, antiglaucoma | ABBOTT LABORATORIES (US) | 1992-07-07 | — | — | US | disclosed |
| US-4420480-A | PARKINSONISM, DEPRESSION, HYPOTENSIVES | MERCK & CO., INC. (US) | 1983-12-13 | — | — | US | disclosed |
| EP-0080115-A2 | Hexahydronaphth(1,2-b)-1,4-oxazines, process for their preparation and pharmaceutical formulation containing them | MERCK & CO. INC. (US) | 1983-06-01 | — | — | EP | disclosed |
| US-4048330-A | Compositions containing 2-(6'-substituted-2'-naphthyl)acetic acid esters used for treating inflammation, pain or pyrexia | SYNTEX CORPORATION (US) | 1977-09-13 | — | — | US | disclosed |
| US-4009197-A | 2-(6-Substituted-2'-naphthyl) acetic acid derivatives and the salts and esters thereof | SYNTEX CORPORATION (PM) | 1977-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233918-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES | MAPT, PRMT1, PSEN1 | NPC1 3364/4885RAB9A 2101/4885SMN1; SMN2 819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.